Compare Abbott Laboratories (ABT) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs NextEra Energy, Inc. — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while NextEra Energy, Inc. trades at $88.29 (market cap $184.51B). The key difference: Abbott Laboratories and NextEra Energy, Inc. are close in size by market cap, and NextEra Energy, Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| ABT | NEE | |
|---|---|---|
Market Cap | $166.94B | $184.51B |
Sector | Health | Utilities |
52-Week High | $136.62 | $97.88 |
52-Week Low | $82.57 | $69.77 |
Enterprise Value | $193.69B | $286.92B |
Dividend Yield | 2.63% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NextEra Energy (NEE) trades at $88.47, up 0.15% today, with a neutral technical outlook and strong analyst support. The stock shows solid fundamentals with a P/E of 22.19, net income margin of 29.37%, and recent earnings beats in Q1 2026. Revenue grew to $27.41B in 2025, though net income dipped slightly to $6.84B. A recent $0.62 dividend underscores shareholder returns, while the Dominion Energy merger positions NEE for AI-driven power demand growth.
Outlook remains positive with a consensus price target of $104.29 (18% upside), driven by clean energy demand and partnerships. Risks include rising debt-to-asset ratios (47.6% in 2025) and regulatory pressures. Institutional sentiment is bullish with 66.7% buy ratings, but investors should monitor execution on capital expenditures and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
